Nucletron announces financial results for the first half year of 2009

Nucletron, a global leader in radiation oncology, today announced strong financial results over the first half year of 2009. Despite challenging global economic conditions, Nucletron surpassed projections for the first half year.

Net sales amounted to EUR 51.2 million, a 3% growth on like-for-like basis compared to the first half of 2008. EBITDA in the first half of 2009 amounted to EUR 6.3 million, a 53% increase compared to EUR 4.1 million over the same period last year. As a result of the positive developments Nucletron expects full year EBITDA to increase to EUR 19.0 million.

Jos Lamers, chief executive officer of Nucletron, comments: "Over the first six months of 2009, we have seen the results of our improved focus on innovation and our increased marketing efforts. Our senior management team is at full strength after the appointment of three new team members with a blue chip background. Combining our strength in marketing and sales with the research & development capabilities of Isodose Control will make Nucletron one of the global leaders in brachytherapy. Given our many upcoming product releases in the months ahead, we are on track to outperform our 2009 goals."

Among the several advancements made in the first half of 2009, Nucletron partnered with Advanced Radiation Therapy (ART) to offer a revolutionary solution for treating breast cancer. AccuBoost allows clinicians to use image-guidance, as used in a standard mammography, to pinpoint radiation directly to the tumour site. This allows for much better accuracy in targeting the radiation to the cancerous area, while protecting the patients' healthy organs during treatment.

The business collaboration with Isodose Control is now in place. The partnership allows clinicians to benefit from Nucletron's leadership and strength in brachytherapy with Isodose Control's track record of innovation.

Additionally, Nucletron launched its latest evolution in treatment planning for radiotherapy. Model-based segmentation in Oncentra MBS and volumetric modulated arc therapy with Oncentra VMAT ensure quality, while dramatically reducing the time needed to create treatment plans.

Source:

NUCLETRON BV

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
New tool predicts nerve damage risk from breast cancer treatment